ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

bicalutamide

Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.

Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.

Drug pageBicalutamide: every studyMany companies study it; this page follows only the 21 they lead. All 94 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Oct 26, 200521 company-led studies, 1 open or runningNext primary completion: Apr 24, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca130 open or runningphase 4since Oct 26, 2005Oct 16, 2004none ahead
Alessa Therapeuticsits history only21 open or runningphase 1since Feb 12, 2020Feb 12, 2020Apr 24, 2027phase 1 · NCT04943536
Kremers Urban Developmentits history only20 open or runningphase 1since Dec 23, 2009Dec 23, 2009none ahead
Novartisits history only20 open or runningphase 1since Aug 13, 2009Aug 13, 2009none ahead
Teva Pharmaceutical Industriesits history only20 open or runningphase 1since Sep 8, 2009Sep 8, 2009none ahead

Also a collaborator on its studies: AbbVie.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AstraZeneca only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 16, 2004First study: phase 2 study in Puberty, PrecociousFirst studyNCT00094328 · 14 enrolled · United States, Canada, France and more
  2. Oct 26, 2005Phase 4 study in Prostatic NeoplasmsNCT00255268 · 15 enrolled · Mexico
  3. Dec 28, 2007Phase 4 study in Prostatic NeoplasmsNCT00590213 · 125 enrolled · Turkey
  4. Mar 12, 2008Phase 2 study in GynecomastiaNCT00637871
  5. Apr 7, 2008Phase 3 study in Prostatic NeoplasmsNCT00657904 · 3,618 enrolled · United States, Canada
  6. May 2, 20082 phase 3 studies in Prostatic NeoplasmsNCT00673205, NCT00672282
  7. Feb 18, 2009Phase 3 study in Prostatic NeoplasmsNCT00846976 · 101 enrolled · United States
  8. Aug 11, 20114 phase 1 studies in HealthyNCT01415791, NCT01415778, NCT01416883 and 1 more
  9. Mar 21, 2019Phase 4 study in Advanced Prostate CancerNCT03971110 · 9 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 13 AstraZeneca leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03971110Advanced Prostate Cancer · China4TerminatedNov 9, 20229
NCT01416883Healthy1TerminatedAug 20108
NCT01416870Healthy1TerminatedNov 2010102
NCT01415791Healthy1CompletedSep 20118
NCT01415778Healthy1CompletedNov 201148
NCT00846976Prostatic Neoplasms · United States3CompletedJun 2013101
NCT00673205Prostatic Neoplasms · Australia, Austria, Belgium and more3CompletedAug 20083,588
NCT00672282Prostatic Neoplasms · Denmark, Finland, Norway and more3Completed1,218
NCT00657904Prostatic Neoplasms · United States, Canada3CompletedJul 20083,618
NCT00637871Gynecomastia2CompletedJun 2005
NCT00590213Prostatic Neoplasms · Turkey4Completed125
NCT00255268Prostatic Neoplasms · Mexico4Withdrawn15
NCT00094328Puberty, Precocious · United States, Canada, France and more2CompletedMay 22, 200814

How it is read

Names in the registry

  • “Bicalutamide”, 9 entries
  • “ICI176,334-1”, 4 entries
  • “bicalutamide”, 2 entries
  • “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
  • “Casodex 80 mg tablet”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.